Regulus Therapeutics
RGLS
#7200
Rank
A$0.85 B
Marketcap
A$12.33
Share price
0.00%
Change (1 day)
423.09%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -A$72.73 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -A$69.8 Million a decrease over its 2023 earnings that were of -A$44.47 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -A$72.73 Million4.19%
2024 -A$69.8 Million56.97%
2023 -A$44.47 Million6.51%
2022 -A$41.75 Million2.53%
2021 -A$40.72 Million93.59%
2020 -A$21.04 Million-15.41%
2019 -A$24.87 Million-64.46%
2018 -A$69.96 Million-33.26%
2017 -A$0.11 Billion-13.98%
2016 -A$0.13 Billion44.77%
2015 -A$84.18 Million-1.63%
2014 -A$85.58 Million203.6%
2013 -A$28.19 Million8.65%
2012 -A$25.95 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
A$11.76 B-16,520.40%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
A$0.67 B-1,038.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$17.12 B-23,992.56%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
A$22.79 B-31,913.87%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
A$10.80 B-15,184.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-A$0.17 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-A$0.18 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
A$1.84 B-2,675.32%๐Ÿ‡บ๐Ÿ‡ธ USA